

Biocept Inc. Investor Relations Department 5810 Nancy Ridge Drive San Diego, CA 92121 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: BIOC	
Last Trade:	1.40
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.74 - 3.39
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumorassociated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests perfor... (more)

## **Stock Performance**



## Press Releases [View all]

Jul 14, 2017

Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection

Jun 26, 2017

Biocept Added to the Russell Microcap Index

Jun 21, 2017

Biocept and MediNcrease Health Plans
Announce Provider Agreement Expanding
Access to Liquid Biopsy Testing

May 22, 2017

Biocept Awarded U.S. Patent with Broad
Claims for Antibody Capture of Targets of
Interest on Any Solid Surface Including
CTCs and Other Materials Shed by Solid
Tumors into Blood

May 18, 2017

Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign

## Financials [View all]

First Quarter Financial Results

Mar 28, 2017

Annual Report (10-K)

Mar 30, 2017

Proxy Statement (DEF 14A)

May 15, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)